Matthew Cooperberg, MD

Genitourinary oncologist

Dr. Matthew Cooperberg is a genitourinary cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center. He specializes in the diagnosis and management of genitourinary cancer, and using minimally invasive techniques to treat benign and malignant diseases. Cooperberg, who is interested in new technologies, performs robotic, laparoscopic, endoscopic and percutaneous surgeries. He developed a new prostate cancer risk assessment tool called the Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score.

Cooperberg earned a medical degree and master's of public health at Yale University. He then completed training in general surgery and urology at UCSF, followed by a urologic oncology fellowship under the guidance of Dr. Peter Carroll. Cooperberg is a candidate member of the American Urological Association (AUA), Western Section of the AUA and the American College of Surgeons. He has written over 50 peer-reviewed scientific articles, nine chapters and has lectured nationally and internationally about malignant and benign urologic disease, with a particular focus on prostate cancer.


Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Medical Oncology Phone: (415) 476-4616
Surgical Oncology Phone: (415) 353-7171
Medical Oncology Fax: (415) 353-7107
Surgical Oncology Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
New Patient Fax: (415) 514-6195
General Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Board Certification


More about Matthew Cooperberg

Additional Languages



Yale University School of Medicine 2000


UCSF Medical Center, Urology 2008

Selected Research and Publications

  1. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Sep 07.
  2. Osterberg EC, Palmer NRA, Harris CR, Murphy GP, Blaschko SD, Chu C, Allen IE, Cooperberg MR, Carroll PR, Breyer BN. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urol Oncol. 2017 Aug 17.
  3. Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Jul 19.
  4. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2017 Jul 14.
  5. Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. Biopsy Detected Gleason Pattern 5 Is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. J Urol. 2017 Jul 11.
  6. Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer. 2017 Jun 29.
  7. Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer. 2017 Jun 27.
  8. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2017 Aug; 24(8):611-617.
  9. Cooperberg MR. The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening. Eur Urol. 2017 Sep; 72(3):326-328.
  10. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 May 18.
  11. Cooperberg MR, Chan JM. Epidemiology of prostate cancer. World J Urol. 2017 Jun; 35(6):849.
  12. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 May 11.
  13. Downer MK, Stampfer MJ, Cooperberg MR. Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not? JAMA Oncol. 2017 May 11.
  14. Herlemann A, Cowan JE, Carroll PR, Cooperberg MR. Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. Eur Urol. 2017 May 09.
  15. Eapen RS, Herlemann A, Washington SL, Cooperberg MR. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Curr Opin Urol. 2017 May; 27(3):205-209.
  16. Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. 2017 Apr 08.
  17. Kim CS, Lee JY, Chung BH, Kim WJ, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Wu TL, Lojanapiwat B, Türkeri L, Murphy DG, Gardiner RA, Moretti K, Cooperberg M, Carroll P, Mun SK, Hinotsu S, Hirao Y, Ozono S, Horie S, Onozawa M, Kitagawa Y, Kitamura T, Namiki M, Akaza H. Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate Int. 2017 Sep; 5(3):95-103.
  18. Howard LE, Moreira D, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017 Mar 28.
  19. Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. J Clin Oncol. 2017 Jun 10; 35(17):1898-1904.
  20. Vertosick EA, Vickers AJ, Cowan JE, Broering JM, Carroll PR, Cooperberg MR. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. J Urol. 2017 Sep; 198(3):671-677.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.